CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade

CytomX Therapeutics, Inc. (NASDAQ:CTMX) gapped up prior to trading on Thursday after Barclays raised their price target on the stock from $10.00 to $16.00. The stock had previously closed at $4.40, but opened at $4.51. Barclays currently has an overweight rating on the stock. CytomX Therapeutics shares last traded at $4.8370, with a volume of 3,503,792 shares.

A number of other analysts also recently issued reports on CTMX. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $7.00 to $12.00 in a research report on Monday. Cantor Fitzgerald upped their price objective on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Piper Sandler raised their target price on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. HC Wainwright lifted their target price on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Monday. Finally, Wedbush boosted their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.22.

Insider Buying and Selling at CytomX Therapeutics

In other news, insider Yu-Waye Chu sold 21,279 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $136,611.18. Following the transaction, the insider owned 189,446 shares in the company, valued at approximately $1,216,243.32. The trade was a 10.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher Ogden sold 19,323 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the sale, the chief financial officer directly owned 296,948 shares of the company’s stock, valued at approximately $1,906,406.16. This trade represents a 6.11% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 191,063 shares of company stock valued at $1,226,624. Corporate insiders own 6.60% of the company’s stock.

Key Stories Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Several brokerages raised ratings/targets, boosting sentiment — Barclays raised its target to $16 (overweight). Article Title
• Positive Sentiment: Guggenheim increased its price target to $15 and kept a Buy rating, supporting upside expectations. Article Title
• Positive Sentiment: Wedbush raised its price target to $11, and JPMorgan reportedly upgraded the stock — multiple upgrades are driving positive analyst momentum. Wedbush Article JPMorgan Article
• Neutral Sentiment: HC Wainwright cut near‑term EPS forecasts (Q1–Q4 2026 and FY2026/2027) but retained a Buy rating and a $17 target — mixed signal (lowered estimates but continued bullish view). MarketBeat Report
• Neutral Sentiment: Short-interest data in the feed appears anomalous (shows zero shares) and likely does not provide meaningful directional signal today.
• Negative Sentiment: CytomX priced an underwritten offering of common stock and pre‑funded warrants to raise up to $250M gross (closing expected March 19); markets often view such equity raises as dilutive, which can pressure the stock despite providing runway for trials. Offering Release
• Negative Sentiment: Related coverage notes net proceeds of about $234M from the offering — confirms material dilution magnitude and why some traders sold into the raise. TipRanks Article
• Negative Sentiment: Insider selling: CFO Christopher Ogden sold 19,323 shares and SVP Marcia Belvin sold 31,492 shares on March 17 — disclosed on SEC Form 4 filings; insider sales can be read negatively by the market. CFO Form 4 SVP Form 4
• Negative Sentiment: Recent quarterly results missed expectations (EPS and revenue), which was cited as a reason for an intra‑day pullback earlier this week. Earnings Reaction

Institutional Trading of CytomX Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Orbimed Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the second quarter valued at approximately $19,208,000. Commodore Capital LP purchased a new position in shares of CytomX Therapeutics in the second quarter worth $17,462,000. Perceptive Advisors LLC bought a new stake in CytomX Therapeutics during the 2nd quarter valued at $15,876,000. Franklin Resources Inc. bought a new stake in CytomX Therapeutics during the 2nd quarter valued at $13,096,000. Finally, Vivo Capital LLC purchased a new stake in CytomX Therapeutics during the 2nd quarter valued at $13,096,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Performance

The firm has a market cap of $810.96 million, a PE ratio of -119.13 and a beta of 2.44. The company’s 50-day simple moving average is $5.28 and its two-hundred day simple moving average is $4.10.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. On average, analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.